Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (7 quarters reported)
$277M in Q4 2019 → $978M now. Hover for any quarter.
As reported for the quarter ended June 30, 2021. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Fate Therapeutics, Inc. | 30.0% | Unchanged | 3,379,064 | $293M |
| Arrowhead Pharmaceuticals | 27.6% | Unchanged | 3,260,869 | $270M |
| Protagonist Therapeutics Inc. | 11.2% | Unchanged | 2,449,183 | $110M |
| Cvrx, Inc. | 10.0% | New | 3,495,575 | $97.9M |
| Legend Biotech Corporation | 6.8% | Unchanged | 1,629,173 | $66.9M |
| Meiragtx Holdings PLC | 4.6% | Unchanged | 2,898,550 | $44.9M |
| Fusion Pharmaceuticals Inc. | 3.0% | Unchanged | 3,670,516 | $29.7M |
| Vor Biopharma, Inc. | 2.0% | Unchanged | 1,074,658 | $20M |
| B Biomx Inc. | 1.2% | Unchanged | 2,133,402 | $11.6M |
| TA Therapeutics Acquisition Cor | 1.1% | New | 1,000,000 | $10.3M |
| Adicet Bio, Inc. | 0.8% | Unchanged | 728,944 | $7.5M |
| Phasebio Pharmaceuticals, Inc. | 0.6% | Unchanged | 1,607,044 | $5.98M |
| Aldeyra Therapeutics, Inc. | 0.5% | Unchanged | 394,834 | $4.47M |
| CH Castlight Health Inc. | 0.2% | Unchanged | 811,295 | $2.13M |
| Neuropace, Inc. | 0.1% | New | 55,435 | $1.32M |
| Z Zymergen Inc. | 0.1% | New | 16,553 | $662K |
| Tracon Pharmaceuticals, Inc. | 0.1% | Unchanged | 84,003 | $545K |
| CB Catalyst Biosciences, Inc. | 0.0% | Unchanged | 66,951 | $290K |
| GV Graybug Vision, Inc. | 0.0% | Unchanged | 49,547 | $269K |
| Pulmonx Corporation | 0.0% | Unchanged | 5,639 | $249K |
| Senseonics Holdings, Inc. | 0.0% | Trimmed 89% | 54,621 | $210K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 6 quarters.
quarter ended June 30, 2021 · filed August 03, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Cvrx, Inc. | New | +3,495,575 | +$97.9M | 10.0% |
| TA Therapeutics Acquisition Cor | New | +1,000,000 | +$10.3M | 1.1% |
| Senseonics Holdings, Inc. | Trimmed | −437,648 | −$1.68M | — |
| Neuropace, Inc. | New | +55,435 | +$1.32M | 0.1% |
| Z Zymergen Inc. | New | +16,553 | +$662K | 0.1% |
quarter ended March 31, 2021 · filed May 06, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| VB Vor Biopharma, Lnc. | New | +1,074,658 | +$46.3M | 6.0% |
| Aldeyra Therapeutics, Inc. | Trimmed | −200,000 | −$2.38M | 0.6% |
| Adicet Bio, Inc. | Added | +66,268 | +$867K | 1.2% |
| GV Graybug Vision, Inc. | New | +49,547 | +$275K | — |
| Senseonics Holdings, Inc. | Trimmed | −33,363 | −$88.1K | 0.2% |
quarter ended December 31, 2020 · filed February 09, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| PB Provention Bio, Inc. | Exited | −574,973 | −$7.38M | — |
| Pulmonx Corp | New | +5,639 | +$389K | 0.1% |
| GB Genocea Biosciences, Inc. | Exited | −43,177 | −$99K | — |
quarter ended September 30, 2020 · filed November 03, 2020
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Adicet Bio, Inc. | New | +662,676 | +$7.88M | 1.6% |
| PB Provention Bio, Inc. | Trimmed | −550,000 | −$7.06M | 1.5% |
| GB Genocea Biosciences, Inc. | Trimmed | −100,787 | −$231K | — |
quarter ended June 30, 2020 · filed August 12, 2020
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Fate Therapeutics, Inc. | New | +3,379,064 | +$116M | 22.8% |
| Legend Biotech Corporation | New | +1,629,173 | +$69.3M | 13.6% |
| Fusion Pharmaceuticals Inc. | New | +3,670,516 | +$64.1M | 12.6% |
quarter ended March 31, 2020 · filed May 13, 2020
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Meiragtx Holdings PLC | New | +2,898,550 | +$39M | 21.2% |
Loading...
